Erratum: Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis (Cancer Cell (2009) 15(5) (441–453) (S153561080900110X) (10.1016/j.ccr.2009.03.021));Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis

Cancer Cell

Volumn 15, Issue 5, 2009, Pages 441-453

  Grinkevich, Vera V ^a   Nikulenkov, Fedor ^a   Shi, Yao ^a   Enge, Martin ^a   Bao, Wenjie ^a   Maljukova, Alena ^b   Gluch, Angela ^c   Kel, Alexander ^c   Sangfelt, Olle ^b   Selivanova, Galina ^a  

^a Department of Microbiology   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BIOBASE GMBH   (Germany)

Author keywords

CELLCYCLE

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN E; MICROTUBULE ASSOCIATED PROTEIN 4; MYC PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN RITA; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY MECHANISM; SURVIVAL; TRANSCRIPTION REGULATION;

EID: 65449154815     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.04.014     Document Type: Erratum

References (48)

1. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6 (2005) 635-645
2. Astanehe A., Arenillas D., Wasserman W.W., Leung P.C., Dunn S.E., Davies B.R., Mills G.B., and Auersperg N. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J. Cell Sci. 121 (2008) 664-674
3. Averous J., and Proud C.G. When translation meets transformation: the mTOR story. Oncogene 25 (2006) 6423-6435
4. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., and Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8 (2002) 282-288
5. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400 (1999) 468-472
6. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116 (2003) 1175-1186
7. Enge M., Bao W., Hedström E., Jackson S.P., Moumen A., and Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between poptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 15 (2009) 171-183
8. Felsher D.W., and Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4 (1999) 199-207
9. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
10. Ho J.S., Ma W., Mao D.Y., and Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell. Biol. 25 (2005) 7423-7431
11. Hoffman W.H., Biade S., Zilfou J.T., Chen J., and Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277 (2002) 3247-3257
12. Huettner C.S., Zhang P., Van Etten R.A., and Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24 (2000) 57-60
13. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., and Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (2004) 1321-1328
14. Johnson T.M., Meade K., Pathak N., Marques M.R., and Attardi L.D. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc. Natl. Acad. Sci. USA 105 (2008) 1215-1220
15. Kaeser M.D., and Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99 (2002) 95-100
16. Kimura T., Gotoh M., Nakamura Y., and Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94 (2003) 431-436
17. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., and Gudkov A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285 (1999) 1733-1737
18. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
19. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K.E., Baker L., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13 (2008) 454-463
20. Laptenko O., and Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13 (2006) 951-961
21. Lowe S.W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
22. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
23. Maurer U., Charvet C., Wagman A.S., Dejardin E., and Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21 (2006) 749-760
24. Minsky N., and Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol. Cell 16 (2004) 631-639
25. Miyashita T., Harigai M., Hanada M., and Reed J.C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54 (1994) 3131-3135
26. Murphy M., Hinman A., and Levine A.J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10 (1996) 2971-2980
27. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 10 (2003) 431-442
28. Pelengaris S., Khan M., and Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109 (2002) 321-334
29. Pietrzak M., and Puzianowska-Kuznicka M. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol. Chem. 389 (2008) 383-393
30. Riley T., Sontag E., Chen P., and Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9 (2008) 402-412
31. Selivanova G. p53: fighting cancer. Curr. Cancer Drug Targets 4 (2004) 385-402
32. Shaked H., Shiff I., Kott-Gutkowski M., Siegfried Z., Haupt Y., and Simon I. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. Cancer Res. 68 (2008) 9671-9677
33. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
34. Strohmaier H., Spruck C.H., Kaiser P., Won K.A., Sangfelt O., and Reed S.I. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413 (2001) 316-322
35. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B.T., Qing W., Packman K., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103 (2006) 1888-1893
36. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
37. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
38. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
39. Wade M., Rodewald L.W., Espinosa J.M., and Wahl G.M. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle 7 (2008) 1973-1982
40. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
41. Werner H., Karnieli E., Rauscher F.J., and LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 93 (1996) 8318-8323
42. White D.E., Talbott K.E., Arva N.C., and Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res. 66 (2006) 3463-3470
43. Wingender E., Crass T., Hogan J.D., Kel A.E., Kel-Margoulis O.V., and Potapov A.P. Integrative content-driven concepts for bioinformatics "beyond the cell". J. Biosci. 32 (2007) 169-180
44. Wysocka J., Reilly P.T., and Herr W. Loss of HCF-1-chromatin association precedes temperature-induced growth arrest of tsBN67 cells. Mol. Cell. Biol. 21 (2001) 3820-3829
45. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
46. Yada M., Hatakeyama S., Kamura T., Nishiyama M., Tsunematsu R., Imaki H., Ishida N., Okumura F., Nakayama K., and Nakayama K.I. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23 (2004) 2116-2125
47. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (2005) 547-559
48. Zhu N., Gu L., Findley H.W., and Zhou M. Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Biochem. Biophys. Res. Comm. 335 (2005) 1272-1279